Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer

This is a Phase II prospective single-arm trial that is recruiting 80 participants from patients that have biochemical failure after radical prostatectomy with local or regional recurrence proven by PSMA PET. Participants of this study will receive molecular imaging informed radiation dose escalation to site of recurrent disease and de-escalation to uninvolved areas. Participants will be follow-up as per standard of care up to 5 years post-treatment.

Trial Details

NCT ID
NCT05328505
Phase
NA
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Image-guided Radiotherapy
Locations (sample)
  • London, Ontario, Canada|42.98339,-81.23304
  • Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • Men older than 18 years old.
  • Histologically proven initial diagnosis of adenocarcinoma prostate cancer.
  • Previous radical prostatectomy.
  • Biochemical relapse with local or regional recurrence proven on PSMA PET.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →